Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893557 | 0.89 | GABRA2 (0.40) | GABRA2GABRB2MDM2OGFRL1OPRM1 | |
| SCHEMBL1437446 | 0.85 | KDM4E (0.40) | GABRA2GABRB2MDM2OGFRL1OPRM1 | |
| SCHEMBL1437109 | 0.84 | MDM2 (0.57) | PTGDR2GABRA2GABRB2MDM2 | |
| SCHEMBL1437265 | 0.82 | MDM2 (0.42) | MDM2OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL9893997 | 0.81 | GABRA2 (0.48) | PTGDR2GABRA2GABRB2 | |
| SCHEMBL9893701 | 0.79 | MDM2 (0.53) | MDM2OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1437197 | 0.77 | MDM2 (0.58) | GABRA2GABRB2MDM2 | |
| SCHEMBL1437404 | 0.76 | MDM2 (0.53) | GABRA2GABRB2MDM2 | |
| SCHEMBL9893599 | 0.75 | MDM2 (0.57) | GABRA2GABRB2MDM2TARBP2 | |
| SCHEMBL9894410 | 0.75 | BCL9 (0.40) | MDM2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | PTGDR2 4007/4885PTGDR 3031/4885PTGER2 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.